At a glance
ClinicalIndex Comparison RecordN/ACompleted· 20 enrolled
Drug / intervention
Celebrex +1 moredrug
Likely dose
Celebrex 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effect of a Non-hormonal Cox-2 Inhibitor (Celebrex) on Ovulation
In Brief
A clinical study evaluating Celebrex and Placebo for Ovulation and Luteal Development. Completed, enrolled 20 participants across 1 site.
Detailed Summary
The purpose of this study is to assess the effect that Celebrex (a COX-2 inhibitor and non-steroidal anti-inflammatory drug) has on ovulation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvulation, Luteal Development
CountriesUnited States
CollaboratorsSociety of Family Planning
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2009
First PostedMay 2010
Primary CompletionSep 2011
TodayJul 2026
First PostedMay 24, 2010
Enrollment StartSep 1, 2009
Primary CompletionSep 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 16.1 years ago
Interventions
Celebrexdrug
400 mg PO daily intermittently based on hormone and ultrasound findings
Placebodrug
Placebo identical to celecoxib